Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Presence of established diagnosis of active psoriatic arthritis for at least 6 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria
Active PsA defined as the presence of at least 3 (out of 68) tender and at least 3 (out of 66) swollen joints
Presence of active plaque psoriasis with a BSA ≥3%
Men must agree to use a reliable method of birth control or remain abstinent during the study
Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment
Have had an inadequate response when treated with 1 or more conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)
You may not be if
Current or prior use of biologic agents for treatment of Ps or PsA
Evidence of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA
Have participated in any study with interleukin 17 (IL-17) antagonists, including ixekizumab
Serious disorder or illness other than psoriatic arthritis
Serious infection within the last 3 months
Active Crohn's disease or active ulcerative colitis
Active vasculitis or uveitis
Diagnosis of or history of malignant disease \<5 years prior to randomization
Women who are breastfeeding
Clareo Health | A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
